Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.

Cobanoglu, Nazan; Ozcelik, Ugur; ÇAKIR, Erkan; Eyuboglu, Tugba; PEKCAN, SEVGİ; Cinel, Guzin; Yalcin, Ebru; Kiper, Nural; EMİRALİOĞLU, NAGEHAN; ŞEN, VELAT; ŞEN, HADİCE; Ercan, Omur; Cokugras, Haluk; Kilinc, Ayse; Al Shadfan, Lina; YAZAN, HAKAN; ALTINTAŞ, DERYA; Karagoz, Dilek; DEMİR, ESEN; Ozturk, Gokcen; BİNGÖL, AYŞEN; Basaran, Abdurrahman; SAPAN, NİHAT; ÇEKİÇ, ŞÜKRÜ; ÇELEBİOĞLU, EBRU; ASLAN, AYŞE; Gursoy, TUĞBA; Tugcu, Gokcen; Ozdemir, DİLEK; HARMANCI, KORAY; Yildirim, Gonca; KÖSE, MEHMET; Hangul, Melih; Tamay, Zeynep; Suleyman, Ayse; YÜKSEL, HASAN; YILMAZ, ÖZGE; Ozcan, Gizem; TOPAL, ERDEM; Can, Demet; KORKMAZ EKREN, PERVİN; ÇALTEPE, GÖNÜL; KILIÇ, MEHMET; Ozdogan, Sebnem; DOĞRU ERSÖZ, DENİZ

doi:10.1002/ppul.24854

Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.

Cobanoglu N., Ozcelik U., ÇAKIR E., Eyuboglu T. S., PEKCAN S., Cinel G., ...Daha Fazla

Pediatric pulmonology, cilt.55, sa.9, ss.2302-2306, 2020 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 55 Sayı: 9
Basım Tarihi: 2020
Doi Numarası: 10.1002/ppul.24854
Dergi Adı: Pediatric pulmonology
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Sayfa Sayıları: ss.2302-2306
Çukurova Üniversitesi Adresli: Evet

Özet

Background A better understanding of cystic fibrosis transmembrane conductance regulator biology has led to the development of modulator drugs such as ivacaftor, lumacaftor-ivacaftor, tezacaftor-ivacaftor, and elexacaftor-tezacaftor-ivacaftor. This cross-sectional study evaluated cystic fibrosis (CF) patients eligible for modulator drugs.